Lobbying disclosures · Lobbying report
EBS: second_quarter 2026 lobbying report
- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical
Follow EBS- Became public
- Jul 14, 2026, 12:00 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 7:18 PM EST
Why this is connected
Exact legal-name match: Emergent BioSolutions Inc. (https://www.sec.gov/Archives/edgar/data/1367644/).
Reported lobbying amounts
Expenses: $510,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/72d01f94-8497-48af-801e-c09160ad0f54/","filing_uuid":"72d01f94-8497-48af-801e-c09160ad0f54","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/72d01f94-8497-48af-801e-c09160ad0f54/print/","filing_document_content_type":"text/html","income":null,"expenses":"510000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"LIZ HANPETER","dt_posted":"2026-07-14T12:00:42-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue, NW","registrant_address_2":"SUITE 1225","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":304931,"url":"https://lda.gov/api/v1/registrants/304931/","house_registrant_id":38213,"name":"EMERGENT BIOSOLUTIONS INC.","description":null,"address_1":"1455 Pennsylvania Avenue, NW","address_2":"SUITE 1225","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"LIZ HANPETER","contact_telephone":"+1 202-270-7978","dt_updated":"2026-07-15T20:43:59.852894-04:00"},"client":{"id":181344,"url":"https://lda.gov/api/v1/clients/181344/","client_id":12,"name":"EMERGENT BIOSOLUTIONS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-26"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47773,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"FRECH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145839,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FITTING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150489,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47773,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"FRECH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145839,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FITTING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150489,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47773,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"FRECH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145839,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FITTING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150489,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Reauthorization of Protecting Americans from All-Hazards Preparedness Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY27 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 Tribal Opioid Response Grant funding for FY27 H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone H.R. 5252, Having Overdoes Protection Equipment Act Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47773,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"FRECH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145839,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FITTING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150489,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"BARNES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in EBS
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Jan 10, 2025$1K–$15K
Rep. Steve Cohen (D-TN-9)
Sold Emergent BioSolutions EBS
$1K–$15K · Traded Dec 11, 2024 · disclosed Jan 10, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.